Last reviewed · How we verify
NKTR118 Formulation 3a
At a glance
| Generic name | NKTR118 Formulation 3a |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NKTR118 Formulation 3a CI brief — competitive landscape report
- NKTR118 Formulation 3a updates RSS · CI watch RSS
- AstraZeneca portfolio CI